IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE,Australia and INDIANAPOLIS,April 16,2025-- Telix Pharmaceuticals Limited (ASX: TLX,NASDAQ: TLX,Telix,the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX